These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9392584)

  • 1. SMI-31 immunoreactivity in inclusion body myositis.
    Spuler S; Engel AG
    Ann Neurol; 1997 Nov; 42(5):815. PubMed ID: 9392584
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is inclusion body myositis a true myositis?].
    Serratrice G
    Rev Rhum Ed Fr; 1993 Mar; 60(3):187-8. PubMed ID: 8293003
    [No Abstract]   [Full Text] [Related]  

  • 3. High dose immunoglobulin therapy in a case of inclusion body myositis: clinical and immunologic aspects.
    Salvarani C; Boiardi L; Maldini MC; Mancini R; Rinaldi M; Macchioni P; Portioli I
    J Rheumatol; 1993 Aug; 20(8):1455-6. PubMed ID: 8230050
    [No Abstract]   [Full Text] [Related]  

  • 4. Controlling autoimmunity in sporadic inclusion-body myositis.
    Steinman L
    Neurology; 2006 Jan; 66(2 Suppl 1):S56-8. PubMed ID: 16432146
    [No Abstract]   [Full Text] [Related]  

  • 5. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis.
    Salajegheh M; Pinkus JL; Nazareno R; Amato AA; Parker KC; Greenberg SA
    Muscle Nerve; 2009 Oct; 40(4):520-8. PubMed ID: 19626672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inclusion body myositis].
    Tomé FM; Fardeau M
    Rev Prat; 1988 Oct; 38(22):1529-32. PubMed ID: 2849800
    [No Abstract]   [Full Text] [Related]  

  • 7. Inclusion body myositis: new concepts.
    Sekul EA; Dalakas MC
    Semin Neurol; 1993 Sep; 13(3):256-63. PubMed ID: 8272596
    [No Abstract]   [Full Text] [Related]  

  • 8. Inclusion body myositis and chronic immune thrombocytopenia.
    Riggs JE; Schochet SS; Gutmann L; McComas CF; Rogers JS
    Arch Neurol; 1984 Jan; 41(1):93-5. PubMed ID: 6316880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele.
    Askanas V; Engel WK; Alvarez RB; Frangione B; Ghiso J; Vidal R
    Ann Neurol; 2000 Apr; 47(4):544-9. PubMed ID: 10762172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dilemma of treating patients with inclusion body myositis.
    Wortmann RL
    J Rheumatol; 1992 Sep; 19(9):1327-9. PubMed ID: 1331440
    [No Abstract]   [Full Text] [Related]  

  • 11. [Myositis with inclusion bodies].
    Carpenter S; Karpati G
    Med Clin (Barc); 1989 Jun; 93(4):139-40. PubMed ID: 2552236
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inclusion body myositis. An underdiagnosed disease with creeping muscular fatigue].
    Lindberg C; Oldfors A
    Lakartidningen; 1995 Mar; 92(10):973-6. PubMed ID: 7885097
    [No Abstract]   [Full Text] [Related]  

  • 13. [Idiopathic inflammatory myopathies].
    Figarella-Branger D; Lacroix C; Coquet M; Gherardi R; Pellissier JF
    Ann Pathol; 2001 Jun; 21(3):279-84. PubMed ID: 11468572
    [No Abstract]   [Full Text] [Related]  

  • 14. beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis.
    Askanas V; Engel WK; Alvarez RB; Glenner GG
    Lancet; 1992 Feb; 339(8792):560-1. PubMed ID: 1346915
    [No Abstract]   [Full Text] [Related]  

  • 15. Inclusion body myositis.
    Mendell JR; Sahenk Z
    Neurology; 1992 Nov; 42(11):2231-2. PubMed ID: 1279467
    [No Abstract]   [Full Text] [Related]  

  • 16. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion body myositis associated with hepatitis C virus infection.
    Tsuruta Y; Yamada T; Yoshimura T; Satake M; Ogata K; Yamamoto T; Furuya H; Kira J
    Fukuoka Igaku Zasshi; 2001 Nov; 92(11):370-6. PubMed ID: 11774706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity binding of inclusion bodies on supermacroporous monolithic cryogels using labeling with specific antibodies.
    Ahlqvist J; Kumar A; Sundström H; Ledung E; Hörnsten EG; Enfors SO; Mattiasson B
    J Biotechnol; 2006 Mar; 122(2):216-25. PubMed ID: 16442653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inclusion bodies of human cytomegalovirus are composed of the DNA and immediately early and early antigens of the virus].
    Yan QG; Huang GS; Guo Y; Wang Z; Feng JL; Yang GR
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):262-5. PubMed ID: 15340573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, purification, and in vitro refolding of a humanized single-chain Fv antibody against human CTLA4 (CD152).
    Chen LH; Huang Q; Wan L; Zeng LY; Li SF; Li YP; Lu XF; Cheng JQ
    Protein Expr Purif; 2006 Apr; 46(2):495-502. PubMed ID: 16243538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.